Very very honoured to have our prostate research win both best oral and poster presentation at #bug16. A testament to the collaborative work of the Urooncological teams at Barts, UCLH, and Barnet towards improving patient outcomes Shiv Smith 💙 @Michelle_Barts

The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis #VisualAbstract Robert Huddart💙 Nuria Porta europeanurology.com/article/S0302-…

Early bird closes 17th February Book your place nationalgermcellgroup.org.uk

At #GU20 San Francisco. Our work from @BartsHospital, London across 20 yrs of data studying outcomes by ethnicity in mCRPC PCa has gained an ASCO Merit Award and selected for the Poster Walk highlight today. #BAME JShamash Barts Cancer Team Charles Knight OBE Barts Cancer Team 5A_GHF Prostate Cancer UK

#GU20 From 425 patients, Black pts with mCRPC don’t do worse than White men (HR 0.81, p=0.08). For the 106 patients who did not receive any chemo, Black pts did better (HR 0.54, p=0.019). Incidence may be higher in Black men, but outcomes are similar or better! Prostate Cancer UK #BAME

I'm thrilled to see these data . From a man who was instrumental in my career guidance and inspiration Follow us on Bluesky @ICR-CTSU

Despite higher incidence of prostate cancer in black men, outcomes the same if not better than white men in mCRPC - with indication of contribution to survival derived from hormone-based treatment Prostate Cancer UK @ThePCRC Prostate Awareness

Our work at @BartsHospital published in BJU International today shows neutropenic fever admissions decrease by substituting high-dose #dexamethasone for olanzapine as antiemetic in BEP regimen. #QOL bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.11… JShamash Charles Knight OBE @StBartsTCGroup Testicular Cancer Society Testicular Cancer

This is the story of our testis supraregional network: changes in centralised path and radiology diagnosis and eventual improvement in outcome over 10 years serving 7.5 million people. British Journal of Cancer #testis cancer doi.org/10.1038/s41416…

We are immensely proud to publish this pioneering piece from Barts Health in Prostate Cancer and Prostatic Diseases: the first European-based study to investigate impact of ethnicity on outcomes in metastatic castrate resistant PCa. nature.com/articles/s4139… 1/5 UroToday.com VJ Oncology The Diversity Dashboard

meetinglibrary.asco.org/record/205706/… On behalf of the team, proud to present this Phase II trial abstract in #GU22. We report efficacy and toxicity data of an oxaliplatin-based regimen with high dose methotrexate in relapsed germ cell tumors. UroToday.com Barts Experimental Cancer Medicine Centre @BartsHospital VJ Oncology

GAMMA: Results from a phase II study for relapsed germ cell tumors using an oxaliplatin-based treatment regimen. ascopubs.org/doi/10.1200/JC…. Excited to present this multicentre trial on Saturday on behalf of Barts Experimental Cancer Medicine Centre Daniel Berney JShamash and others! #GU22 #testicularca

Professor Robert Horne and Dr Jonathan Shamash at UCL and Barts Health are investigating how Black men with advanced prostate cancer can be better supported to continue with cancer treatment.